Seratrodast is an inhibitor of the thromboxane A2 receptor and exhibits anti-asthma and anti-inflammatory activity but no anti-platelet benefits. Seratrodast is used clinically to treat asthma, preventing bronchial hyperresponsiveness and bronchoconstriction as well as improving cough threshold.
| Cas No. | 112665-43-7 |
|---|---|
| Purity | ≥98% |
| Formula | C22H26O4 |
| Formula Wt. | 354.44 |
| IUPAC Name | 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoicacid |
| Melting Point | 128-129°C |
| Appearance | Yellow powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | S1968 MSDS PDF |
|---|---|
| Info Sheet | S1968 Info Sheet PDF |
An J, Li JQ, Wang T, et al. Blocking of thromboxane A2 receptor attenuates airway mucus hyperproduction induced by cigarette smoke. Eur J Pharmacol. 2013 Mar 5;703(1-3):11-7. PMID: 23399768.
Dogné JM, de Leval X, Benoit P, et al. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11-7. PMID: 14720071.
Ishiura Y, Fujimura M, Yamamori C, et al. Thromboxane antagonism and cough in chronic bronchitis. Ann Med. 2003;35(2):135-9. PMID: 12795341.
